Clay Siegall is the Chief Executive Officer and also the Founder of Seattle Genetics. He recently had an interview with Inspire where he talked about his life, company and how to become successful. According to Clay Siegall, cancer treatment has been made easier and efficient through targeted therapies and that the old systemic chemotherapies will soon be a thing of the past. Clay Siegall also says that targeted therapies are by far more tolerable compared to the traditional chemotherapies. Clay Siegall told Inspire that since he was young, he was intrigued by medicine, technology power and also the need to overcome the disease.
Clay Siegall became interested in the treatment of cancer while he was at the University of Maryland studying Zoology. This was a member of his family became sick from cancer and at one point developed anemia due to chemotherapy. This got Clay thinking of how to come up with better ways of cancer treatment. At first, Clay Siegall was not interested in the money part of it, but as the company grew, he started making money. Asked how Seattle Genetics makes money, Clay Siegall said that there are several ways the company makes money; by selling its own, proprietary drugs, revenues from production partnerships and also licensing of processes and technologies produced by the enterprise.
Clay Siegall says that hard work is what has led to his success. He also attributes his success to passion, great focus, networking, and discipline. He founded Seattle Genetics in 1998 and had ever since led the company to achieve a tremendous success and growth. The company is specialized in targeted therapy drugs development for diseases that have been unable to experience mortality improvements for many years. Dr. Clay studied at the University of Maryland where he acquired his BS in Zoology. He also got his Ph.D. in Genetics from the George Washington University.
Clay Siegall has managed to steer Seattle Genetics from a small startup to a huge company in the cancer research sector. His mission is to come up with drugs that will effectively prevent and treat cancer and also that are more tolerable to the patient while having minimal side effects.